Aquestive completes $150 million refinancing facility with Oaktree-managed funds

Aquestive Therapeutics announced completion of a five-year $150 million debt refinancing with funds managed by Oaktree on May 12, 2026. At closing $55 million was advanced, primarily to repay $45 million of existing debt. Further $20 million and $25 million advances depended on regulatory and sales milestones, and an additional optional $50 million tranche required mutual consent. The facility headline is not fully funded principal.